COMPANY

7 Hills Pharma

HQ: Houston, TX source · 7hillspharma.com ↗ · Southwest

Keywords: oncology cancer small molecule hematology influenza Melanoma Metastasis Pleural Mesothelioma Renal Cell Carcinoma MSI-High Mismatch Repair Deficiency Colorectal Cancer Hepatocellular Carcinoma Hepatocellular Cancer Renal Cell Cancer Kidney Cancer Skin Cancer Non Small Cell Lung Cancer NSCLC ALK Genomic Tumor Aberrations 7HP349

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)17NIH grants

Timeline

Aug 23, 2024 Trial start Phase 1/Phase 2: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy source ↗
Oct 28, 2020 Trial start 1: A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects source ↗

Upcoming milestones

Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · NCT06362369

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06362369	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	Phase 1/Phase 2	Recruiting	Aug 23, 2024	Dec 31, 2027 (estimated)
NCT04508179	A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects	1	Completed	Oct 28, 2020	Oct 25, 2021 (actual)

NIH awards 17

Annual award amounts. Total $13.9M.

Jul 30, 2024 NIH award 5R44CA285207-02 FY2024: $999,200 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. 7HP349, an Integrin Activator to Treat Patien source ↗
Jun 28, 2024 NIH award 5R44AI172437-03 FY2024: $997,867 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Integrin activator-adjuvanted DNA vaccine aga source ↗
Mar 27, 2024 NIH award 5R44AI176894-02 FY2024: $953,477 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. 7HP349, an oral integrin activator to augment source ↗
Sep 19, 2023 NIH award 1R44CA285207-01 FY2023: $999,200 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. 7HP349, an Integrin Activator to Treat Patien source ↗
Jun 26, 2023 NIH award 5R44AI172437-02 FY2023: $997,867 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Integrin activator-adjuvanted DNA vaccine aga source ↗
Apr 25, 2023 NIH award 1R44AI176894-01 FY2023: $928,224 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. 7HP349, an oral integrin activator to augment source ↗
Jul 13, 2022 NIH award 1R44AI172437-01 FY2022: $999,300 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Integrin activator-adjuvanted DNA vaccine aga source ↗
Aug 12, 2021 NIH award 5R44CA250646-02 FY2021: $1,015,591 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Development of 7HP349, an oral integrin act source ↗
Apr 30, 2021 NIH award 1R43AI162169-01 FY2021: $297,724 awarded for that fiscal year; activity R43 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Integrin Activation to Augment SARS-CoV-2 Vac source ↗
Feb 17, 2021 NIH award 5R42HL129612-03 FY2021: $928,941 awarded for that fiscal year; activity R42 (STTR); PI VANDERSLICE, PETER; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. A small molecule integrin activator to enha source ↗
Sep 11, 2020 NIH award 1R44CA250646-01A1 FY2020: $984,409 awarded for that fiscal year; activity R44 (SBIR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Development of 7HP349, an oral integrin act source ↗
Mar 7, 2020 NIH award 2R42HL129612-02 FY2020: $935,957 awarded for that fiscal year; activity R42 (STTR); PI VANDERSLICE, PETER; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. A small molecule integrin activator to enha source ↗
Mar 29, 2019 NIH award 5R42CA203456-03 FY2019: $1,001,898 awarded for that fiscal year; activity R42 (STTR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Development of a small molecule activator o source ↗
Mar 7, 2019 NIH award 1R41AI145507-01 FY2019: $243,282 awarded for that fiscal year; activity R41 (STTR); PI WOODSIDE, DARREN G; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Integrin Activation as a Treatment for Leuk source ↗
Apr 9, 2018 NIH award 2R42CA203456-02A1 FY2018: $999,501 awarded for that fiscal year; activity R42 (STTR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Development of a small molecule activator o source ↗
Aug 27, 2016 NIH award 1R41HL129612-01A1 FY2016: $295,931 awarded for that fiscal year; activity R41 (STTR); PI VANDERSLICE, PETER; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. A small molecule integrin activator to en source ↗
Jun 6, 2016 NIH award 1R41CA203456-01A1 FY2016: $313,705 awarded for that fiscal year; activity R41 (STTR); PI MARATHI, UPENDRA; recipient as written: 7 HILLS PHARMA, LLC, HOUSTON, TX. Development of a small molecule activator o source ↗